Morgan Stanley Targets New All-Time High For Bristol-Myers, Upgrades To Overweight

0 Comments 3 view(s)

Bristol-Myers Squibb Co (NYSE: BMY) stock is up 26.5 percent year-over-year, making a partial recovery from a mid-2016 plunge, and one analyst anticipates upside worthy of a new all-time high.

Latest Ratings for BMY

Date Firm Action From To
Feb 2018 Morgan Stanley Upgrades Equal-Weight Overweight
Feb 2018 BMO Capital Maintains Underperform Underperform
Feb 2018 Leerink Swann Maintains Outperform Outperform

View More Analyst Ratings for BMY

View the Latest Analyst Ratings

read more